Evidence map›Paper›PMID 24989174›Full record

ArticleThe Annals of pharmacotherapy2014

Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy.

Jacques Baillargeon, Randall J Urban, Yong-Fang Kuo, Kenneth J Ottenbacher, Mukaila A Raji, Fei Du, Yu-Li Lin, James S Goodwin

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Annals of pharmacotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03678233 (Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients), which is not on this map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03678233 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

Efficacy of Testosterone Gel to Restore Normal Serum Values of Testosterone During the Acute Phase of Critical Illness in Adult ICU Patients

TypeinterventionalSponsorUniversity Hospital, Clermont-FerrandRan2019 to 2025Enrolled30ConditionsHypermetabolism in ICU, Loss of Muscle Mass, Functional Disability After ICU, ICU Acquired HypogonadismArmsAndroGel 16.2 mg/L
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials.The Journal of clinical endocrinology and metabolism · 2018
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jacques BaillargeonUniversity of Texas Medical Branch, Galveston, TX, USA jbaillar@utmb.edu.
Randall J UrbanUniversity of Texas Medical Branch, Galveston, TX, USA.
Yong-Fang KuoUniversity of Texas Medical Branch, Galveston, TX, USA.
Kenneth J OttenbacherUniversity of Texas Medical Branch, Galveston, TX, USA.
Mukaila A RajiUniversity of Texas Medical Branch, Galveston, TX, USA.
Fei DuUniversity of Texas Medical Branch, Galveston, TX, USA.
Yu-Li LinUniversity of Texas Medical Branch, Galveston, TX, USA.
James S GoodwinUniversity of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · US

Funding

UTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7M
UTMB CLINICAL AND TRANSLATIONAL SCIENCE AWARD: NASA BED REST STUDIESUL1RR029876 · NCRR · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2009 to 2011
$17.7M
UTMB Clinical and Translational Science AwardUL1TR000071 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R. · 2012 to 2014
$14.4M
Patient Centered Outcomes Research in the ElderlyR24HS022134 · AHRQ · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2013 to 2017
$4.8M
Center for Rehabilitation Research Using Large DatasetsR24HD065702 · NICHD · UNIVERSITY OF TEXAS MED BR GALVESTON · PI OTTENBACHER, KENNETH J. · 2010 to 2014
$4.0M
Understanding Mechanisms of Ethnic Disparities in Colorectal Cancer ScreeningR01CA134275 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2008 to 2012
$1.3M
Established Investigator Award in Cancer Prevention & ControlK05CA134923 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GOODWIN, MD, JAMES S. · 2008 to 2019
$1.0M
AHRQ HHS R24 HS022134NCATS NIH HHS UL1 TR000071NCI NIH HHS K05 CA134923NCI NIH HHS R01 CA134275NCRR NIH HHS UL1 RR029876NIA NIH HHS P30 AG024832NICHD NIH HHS R24 HD065702
6 · The paper itself

Abstract

backgroundTestosterone therapy for older men has increased substantially over the past decade. Research on the effects of testosterone therapy on cardiovascular outcomes has yielded inconsistent results.

objectiveTo examine the risk of myocardial infarction (MI) in a population-based cohort of older men receiving intramuscular testosterone.

methodUsing a 5% national sample of Medicare beneficiaries, we identified 6355 patients treated with at least 1 injection of testosterone between January 1, 1997, and December 31, 2005. We matched this cohort to 19 065 testosterone nonusers at a 1:3 ratio based on a composite MI prognostic score. Patients were followed until December 31, 2005, or until they lost coverage from Medicare, enrolled in a health maintenance organization, experienced a MI, or died.

resultIn a Cox regression analysis adjusting for demographic and clinical characteristics, receipt of testosterone therapy was not associated with an increased risk of MI (hazard ratio [HR] = 0.84; 95% CI = 0.69-1.02). In this analysis, there was an interaction between receipt of testosterone and quartile of risk of MI (P = 0.023). For men in the highest quartile of the MI prognostic score, testosterone therapy was associated with a reduced risk of MI (HR = 0.69; 95% CI = 0.53-0.92), whereas there was no difference in risk for the first (HR = 1.20; 95% CI = 0.88-1.67), second (HR = 0.94; 95% CI = 0.69-1.30), and third quartiles (HR = 0.78; 95% CI = 0.59-1.01).

conclusionOlder men who were treated with intramuscular testosterone did not appear to have an increased risk of MI. For men with high MI risk, testosterone use was modestly protective against MI.

Indexed as

myocardial infarctiontestosteronetestosterone replacement therapy

Identifiers

PMID24989174
PMCPMC4282628
OpenAlexW2110692189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.